logo-loader
viewAlliance Pharma PLC

Full interview: Alliance Pharma delivers 'solid' first-half performance with strong cashflow

Alliance Pharma PLC's (LON:APH) Peter Butterfield discusses with Proactive London's Andrew Scott the firm's interim results and says they delivered a solid first-half performance.

Revenues for the period were £70.3mln, up 28% on a constant currency basis, or an organic 10% if the impact of recent purchases was stripped out.

Quick facts: Alliance Pharma PLC

Price: 71 GBX

AIM:APH
Market: AIM
Market Cap: £368.89 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alliance Pharma CEO pleased with strong first half as portfolio performs...

Alliance Pharma PLC's (LON:APH) Peter Butterfield tells Proactive London's Andrew Scott revenues increased by a third in the opening six months of 2019. He says growth's been underpinned by strong demand in Asia for its Kelo-Cote scar treatments. For the first half ended 30 June,...

on 31/7/19

RNS

Director's Dealing

1 week, 4 days ago

Total Voting Rights

2 weeks, 3 days ago

Interim Results

3 weeks, 5 days ago

2 min read